[Therapeutic strategies against myasthenia gravis].

Many patients with myasthenia gravis (MG) still find it difficult to maintain daily activities due to chronic residual fatigability and long-term side effects of oral corticosteroids, since full remission is not common. Our analysis demonstrated that disease severity, oral corticosteroids, and depressive state are the major factors negatively associated with QOL, and that QOL of MM status patients taking < or = 5 mg prednisolne/day is identically good as that seen in CSR and is a target of treatment. In order to achieve early MM or better status with prednisolne < or = 5 mg/day, we advocate the early aggressive treatment strategy that can achieve early improvement by performing an aggressive therapy using combined treatment with plasmapheresis and high-dose intravenous methylprednisolone and then maintain an improved status using low-dose oral corticosteroids and calcineurin inhibitors.
AuthorsKimiaki Utsugisawa, Yuriko Nagane
JournalNihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 71 Issue 5 Pg. 881-6 (May 2013) ISSN: 0047-1852 [Print] Japan
PMID23777099 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Adrenal Cortex Hormones
  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Prednisolone
  • Adrenal Cortex Hormones (administration & dosage, therapeutic use)
  • Calcineurin Inhibitors
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Myasthenia Gravis (drug therapy, surgery)
  • Prednisolone (administration & dosage, therapeutic use)
  • Quality of Life

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: